Calcium channel antagonists: Clinical uses-Past, present and future

Biochemical Pharmacology

Volumn 74, Issue 1, 2007, Pages 1-9

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

1,4 Dihydropyridines; Bone formation; Calcium channel antagonists; Contraception; Diltiazem; Fertility' immune cells; Nifedipine; Pain; Schistosomiasis; Stroke; T cells; Verapamil

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS ATORVASTATIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GABAPENTIN; LISINOPRIL; MIBEFRADIL; NIFEDIPINE; NISOLDIPINE; PLACEBO; PRAZIQUANTEL; PREGABALIN; THIAZIDE DIURETIC AGENT; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL;

ARTICLE; BONE GROWTH; BONE REMODELING; CANCER; CANCER CHEMOTHERAPY; DEGENERATIVE DISEASE; EPILEPSY; HEART FAILURE; HUMAN; IMMUNE FUNCTION TEST; IMMUNOPATHOLOGY; ISCHEMIA; LYMPHOCYTE CULTURE; MALE FERTILITY; MOOD DISORDER; NONHUMAN; PAIN; PRIORITY JOURNAL; SCHISTOSOMIASIS; TUMOR GROWTH;

EID: 34249049430     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.01.016     Document Type: Note

References (75)

1. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17 (1977) 149-166
2. Janis R.A., Silver P., and Triggle D.J. Drug action and cellular calcium regulation. Adv Drug Res 16 (1987) 309-591
3. Epstein M. In: Epstein M. (Ed). Calcium antagonists in clinical medicine. 3rd ed. (2002), Hanley and Belfus, Philadelphia, PA
4. In: McDonough S.I. (Ed). Calcium channel pharmacology (2004), Kluwer Academic/Plenum Publishers, New York
5. Triggle D.J. Calcium antagonists. History and perspective. Stroke 21 Suppl IV (1990) IV-49-IV-58
6. Godfraind T., and Polster P. Etude comparative de medicaments inhibitant la response contractile de vaisseaux isole's d'origine humaine au animale. Therapie 33 (1968) 1209-1217
7. Epstein M. Safety of calcium antagonists as antihypertensive agents: an update. In: Epstein M. (Ed). Calcium antagonists in clinical medicine (2002), Hanley and Belfus, Philadelphia, PA 807-832
8. Pahor M., Psaty B., Alderman M.H., Applegate W.B., Cavazzini C., Williamson J.D., and Furberg C.D. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive agents: a meta-analysis of randomized controlled trials. Lancet 356 (2000) 1949-1954
9. Pahor M., Carbonin P., Guralnick J.M., Havlik C.J., and Furberg C.D. Risk of gastrointestinal hemorrhage with calcium antagonists in hypertensive patients over 67 years old. Lancet 347 (1996) 1061-1065
10. Pahor M., Guralnik J.M., Ferruci L., Corti M.-E., Salive M.E., Cerhan J.R., et al. Calcium channel blockade and incidence of cancer in aged populations. Lancet 348 (1996) 493-497
11. Opie L.H. Calcium channel blockers (CCBs) in hypertension; reappraisal after new trials and major meta-analyses. Am J Hypertens 14 (2001) 1074-1081
12. Angell M. Science on trial (1996), Norton, New York
13. Stelfox H.T., Chua G., O'Rourke K., and Detsky A.S. Conflict of interest in the debate over calcium channel antagonists. N Eng J Med 338 (1998) 101-106
14. Resnick L.M. Why we can't translate clinical trials into clinical practice in hypertension. Am J Hypertens 16 (2003) 421-425
15. Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. NIH Publication 04-5230; August 2004.
16. ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Am Med Assoc 288 (2002) 2981-2997
17. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Giffon N., and Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998) 645-652
18. Dahlof B., Sever P.S., Poulter N., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with and antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized clinical trial. Lancet 366 (2005) 895-906
19. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized clinical trial. J Am Med Assoc 292 (2004) 2217-2226
20. Doering C., and Zamponi G. Calcium channels. In: Triggle D.J., Gopalakrishnan M., Rampe D., and Zheng W. (Eds). Overview of voltage-gated calcium channels. Voltage-gated ion channels as drug targets (2006), Wiley-VCH, Weinheim, Germany pp. 65-83
21. 2+ channels. Trends Pharmacol Sci 19 (1998) 108-115
22. Welling A., Ludwig A., Zimmer S., Klugbauer N., Flockerzi V., and Hofmann F. Alternatively splices IS6 variants of the alpha1C gene determine the tissue-specific dihydropyridine sensitivity of the cardiac and vascular smooth muscle L-type calcium channels. Circ Res 81 (1997) 526-532
23. 2+ antagonists and activators in cultured rat neonatal rat ventricular myocytes. Mol Pharmacol 35 (1989) 541-552
24. Sun J.P., and Triggle D.J. Calcium channel antagonists: cardiovascular selectivity of action. J Pharmacol Exp Therap 274 (1995) 419-426
25. Staats P.S., Yearwood T., Charapata S., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer of AIDS. J Am Med Assoc 291 (2004) 63-70
26. Snutch T.P. Targeting chronic and neuropathic pain: the N-type calciumchannel comes of age. NeuiroRX 2 4 (2005) 662-670
27. 2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 25 (2004) 465-470
28. Yaks T.L. Calcium channels as therapeutic targets in neuropathic pain. J Pain Suppl 1 7 (2006) S13-S30
29. 2+ channels and epilepsy. Eur J Pharmacol 447 (2002) 211-225
30. Khospravani H., and Zamponi G.W. Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol Rev 86 (2006) 941-966
31. Benoff S. Voltage-dependent calcium channels in mammalian spermatozoa. Front Biosci 3 (1998) 1220-1240
32. 2+: a possible maneuver for spermicidal activity. Drug Dev Res 65 (2005) 1-16
33. 2+-conducting channels in the plasma membrane of mammalian sperm. Reproduction 129 (2005) 251-262
34. Darszon A., Acevedo J.J., Galindo B.E., Hernandez-Gonzales E.O., Nishigaki T., and Trevino C.L. Sperm channel diversity and functional multiplicity. Reproduction 131 (2006) 977-988
35. 2+ into mouse sperm. J Biol Chem 275 (2000) 21210-21217
36. Nowak R. Antihypertension drug may double as male contraceptive. J NIH Res 6 (1994) 27-28
37. Ren D., Navarro B., Perez G., Jackson A.C., Hsu F., Tilly J.L., et al. A sperm ion channel required for sperm motility and male fertility. Nature 413 (2001) 603-609
38. Quill T., Sugden S.A., Rossi K.L., Hammer R.E., and Garbers D.L. Hyperactivated sperm motility driven by CatSper2 is required for fertilization. Proc Nat Acad Sci USA 100 (2003) 14869-14874
39. 2+ entry and control of flagellar function in sperm. Proc Nat Acad Sci USA 100 (2003) 14864-14868
40. Lobley A., Perron V., Reynolkds L., Allen L., and Michalovich D. Identification of human and mouse CatSper3 and CatSper4 genes: characterization of a common interaction domain and evidence for expression in testis. Reprod Biol Endocrinol (2003) I53
41. Carlson A.E., Quill T.A., Westenbroek W.E., Schuh S.M., Mille B., and Babcock D.F. Identical phenotypes of CatSper1 and CatSper2 null sperm. J Biol Chem 280 (2005) 32238-32344
42. Quill T.A., Wang D., and Garbers D.L. Insights into sperm cell motility signaling through sNHE and the CatSpers. Mol Cell Endocrinol 250 (2006) 84-92
43. Nikpoor P., Mowla S.J., Movahedin M., Ziaee S.A.-M., and Tircihi T. CatSper gene expression in postnatal development of mouse tests and in subfertile men with deficient sperm motility. Hum Reprod 19 (2004) 124-128
44. Triggle D.J. The 1,4-dihydropyridine nucleus as a pharmacophoric template. Part 1. Actions at ion channels. MiniRev Med Chem 2 (2003) 137-142
45. Guggino S.E., Lajeunesse D., Wagner J.A., and Snyder S.H. Bone remodeling signaled by a dihydropyridine- and phenylalkylamine-sensitive calcium channel. Proc Natl Acad Sci USA 86 (1989) 2957-2960
46. Walker L.M., Publicover S., Preston M.R., Ahmed M.A., and El Haj A.J. Calcium-channel activation and matrix protein upregulation in bone cells in response to mechanical strain. J Cell Biochem 79 (2000) 648-661
47. Wood M.A., Hughes S., Yang Y., and El Haj A.J. Characterizing the efficacy of calcium channel agonist-release strategies for bone tissue engineering applications. J Control Rel 112 (2006) 96-102
48. Wood M.A., Ynag Y., Thomas P.B.M., and El Haj A.J. Using dihydropyridine-release strategies to enhance load effects in engineered human bone constructs. Tissue Eng 12 (2006) 2489-2497
49. Benzaquen L.R., Brugnara C., Byers H.R., Gattoni-Celli S., and Halperin J.A. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med 1 (1995) 534-540
50. Kunzelmann K. Ion channels and cancer. J Mem Biol 205 (2005) 159-173
51. Schonnerr R. Clinical relevance of ion channels for diagnosis and therapy of cancer. J Mem Biol 205 (2005) 175-184
52. Debes J.D., Roberts R.O., and Jacobson D.J. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 13 (2004) 255-259
53. Lory P., Biduad I., and Chemin J. T-type calcium channels in differentiation and proliferation. Cell Calcium 40 (2006) 135-146
54. 2+ channel antagonists Mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms. Mol Pharmacol 62 (2002) 210-219
55. McCalmont W.F., Patterson J.R., Lindenmuth M.A., Heady T.N., Haverstick D.M., Gray L.S., et al. Investigation into the structure-activity relationship of novel concentration-dependent, dual action T-type calcium channel agonist/antagonists. Bioorg Med Chem 13 (2005) 3821-3839
56. Lee J.Y., Park S.J., Park S.J., Lee M.J., Rhim H., Seo S.H., et al. Growth inhibition of cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett 16 (2006) 5014-5017
57. Connolly T.M., and Barrow J.C. Drugs active at T-type channels. In: Triggle D.J., Gopalakrishnan M., Rampe D., and Zheng W. (Eds). Voltage-gated ion channels as drug targets (2006), Wiley-VCH, Weinheim, Germany 84-99
58. McNeil DG. At the old swimming hole, a vicious cycle thrives. New York Times; November 2nd, 2004, http://www.nytimes.com.
59. Redman C.A., Robertson A., Fallon P.G., Modha J., Kusel J.R., Doenhof M.J., et al. Praziquantel: an urgent and exciting challenge. Parasitol Today 12 (1996) 14-20
60. 2+ channels targets of Praziquantel action?. Int J Parasitol 35 (2005) 1-9
61. Kohn A.B., Anderson P.A.V., Roberts-Misterley J.M., and Greenberg R.M. Schistosome calcium channel β subunits. J Biol Chem 276 (2001) 36873-36878
62. 2+ channel β subunit are key to its role in sensitivity to the anti-schistosomal drug Praziquantel. Parasitology 127 (2003) 349-356
63. Pica-Mattoccia L., Valle C., Baso A., Troiani A.R., Vigorosi F., Liberti P., et al. Cytochalasin D abolishes the schistosomicidal activity of Praziquantel. Exp Parasitol 115 (2007) 344-351
64. 1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 103 (2006) 17537-17542
65. Grafton G., and Thwaite L. Calcium channels in lymphocytes. Immunology 104 (2001) 119-126
66. V-like channels in T cells: more than one gatekeeper?. Trends Pharmacol Sci 27 (2006) 361-367
67. Gomes B., Savignac M., Moreau M., et al. Lymphoctye calcium signaling involves dihydropyridine-sensitive L-type calcium channels: facts and controversies. Crit Rev Immunol 24 (2004) 425-447
68. 2+ channels in human T cells. J Biol Chem 279 (2004) 19566-19573
69. Kotturi M.F., and Jefferies W.A. Molecular characterization of L-type calcium channels splice variants expressed in human T lymphocytes. Mol Immunol 42 (2005) 1461-1474
70. Savignac M., Gomes B., Galard A., Narbonette S., Moreau M., and Leclerc C. Dihydropyridine receptors are selective markers of Th2 cells and can be targeted to prevent Th2-dependent immunopathological disorders. J Immunol 172 (2004) 5206-5212
71. Gomes B., Savignac M., Cabral M.D., Paulet P., Moreau M., and Leclerc C. The cGMP/protein kinase G pathway contributes to dihydropyridine-sensitive calcium response and cytokine production in TH2 lymphocytes. J Biol Chem 281 (2006) 12421-12427
72. V channels in T lymphocyte function. Proc Nat Acad Sci USA 103 (2006) 15529-15534
73. 2+ channel β subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse Cell 88 (1997) 385-392
74. Miljanich G.P. Ziconotide: neuronal calcium channel targets for the treatment of chronic pain. Curr Med Chem 11 (2004) 3029-3040
75. Horn J., and Limburg M. Calcium antagonists for ischemic stroke: a systematic review. Stroke 32 (2001) 570-576